Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,604 signal articles · 133 in last 24h · 155,418 total before filter · latest 1h ago
133last 24h
854last 7d
146● bullish (7d)
90● bearish (7d)
214publishers
AllMacro191Earnings104M&A126Regulatory20Product22Analyst19
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
The bond market threat to the AI Boom
Yahoo Finance Video1d agoneutralVIDEO
The bond market threat to the AI Boom

The intensifying global bond market (^TYX, ^TNX, ^FVX) sell-off could be stymying not only Americans' spending power but the progress of the AI build-out as well. Today's Market Hang panel consists of Host Turney Duff, Business Insider Today executive editor Dan DeFrancesco, The Wall Street Skinny co-founders Jen Saarbach and Kristen Kelly, and author Armando Pantoja.

Roku set to clear regulatory hurdles and close Fox deal, says Wedbush
Proactive1d agoneutral
Roku set to clear regulatory hurdles and close Fox deal, says Wedbush

Roku Inc (NASDAQ:ROKU) remains on track to complete its proposed combination with Fox Corporation in the first half of 2027, according to Wedbush, which reiterated its $155 price target and ‘neutral’ rating after meeting with management. The broker said it expects the transaction to overcome...

Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine
Benzinga1d agobearish
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine

Merck & Co. Inc. (NYSE:MRK) on Thursday announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). DME is a serious eye complication of diabetes where high blood sugar damages tiny retinal blood vessels, causing them to leak fluid into the macula (the central part of the retina responsible for sharp vision) and making it swell. BRUNELLO is the first of two Phase 2b/3 trials evaluating remigromig (MK-3000, formerly EYE103), an investigational

Don’t wait for cheaper stocks — Rebecca Walser on stocks to buy now
TheStreet1d agobullishVIDEO
Don’t wait for cheaper stocks — Rebecca Walser on stocks to buy now

Rebecca Walser of Walser Wealth Management says we’re at the cheapest price entry point of the largest innovation cycle in history. She breaks down where retail investors should put money now, from ASML and Micron to energy and gold, and why “you will be a laggard if you don’t participate.”

Uber’s Mobility strategy supports margin growth, Jefferies says
Proactive1d agoneutral
Uber’s Mobility strategy supports margin growth, Jefferies says

Jefferies reiterated its $110 price target on Uber Technologies Inc (NYSE:UBER, XETRA:UT8) and maintained the company as its ‘Franchise Pick’, saying its expanding Mobility product suite can support faster bookings growth while allowing margins to expand. The broker raised its estimates after...